|
GB1142508A
(en)
*
|
1966-04-27 |
1969-02-12 |
Whitefin Holding Sa |
Pyrrole derivatives
|
|
GB1154744A
(en)
*
|
1966-05-17 |
1969-06-11 |
Whitefin Holding Sa |
Disubstituted Aminoethanols
|
|
BR9907228A
(pt)
|
1998-01-23 |
2000-10-24 |
Nat Jewish Med & Res Center |
Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória
|
|
US7842470B2
(en)
|
2001-10-09 |
2010-11-30 |
Oregon Health & Science University |
Method for pharmacoperones correction of GnRHR mutant protein misfolding
|
|
US20060148767A1
(en)
|
2001-12-06 |
2006-07-06 |
George Cioca |
Use of acyl salicylates as heat shock inducers
|
|
CA2545433A1
(en)
|
2003-11-12 |
2005-05-26 |
Amicus Therapeutics Inc. |
Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
|
|
EP3782655A1
(en)
|
2005-05-17 |
2021-02-24 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
|
AU2006254796B2
(en)
|
2005-06-08 |
2012-08-16 |
Amicus Therapeutics, Inc. |
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
|
|
US20070207992A1
(en)
|
2006-02-21 |
2007-09-06 |
Board Of Trustees Of Michigan State University |
Geldanamycin derivatives and method of use thereof
|
|
WO2007131034A1
(en)
|
2006-05-03 |
2007-11-15 |
The Regents Of The University Of Michigan |
Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
|
|
PL2533050T6
(pl)
|
2006-05-16 |
2016-05-31 |
Amicus Therapeutics Inc |
Możliwości leczenia choroby Fabry'ego
|
|
PL1860101T3
(pl)
|
2006-05-24 |
2011-10-31 |
Amicus Therapeutics Inc |
Sól winianu izofagominy i sposoby zastosowania
|
|
WO2007150064A2
(en)
|
2006-06-23 |
2007-12-27 |
Amicus Therapeutics, Inc. |
METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
|
|
US8143269B2
(en)
*
|
2008-10-03 |
2012-03-27 |
Calcimedica, Inc. |
Inhibitors of store operated calcium release
|
|
KR20120117905A
(ko)
*
|
2010-01-28 |
2012-10-24 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
프로테아좀 활성을 향상시키는 조성물 및 방법
|
|
US8785490B2
(en)
*
|
2010-04-09 |
2014-07-22 |
University Of Louisville Research Foundation, Inc. |
Compounds for treating disease, for administering, and for pharmaceutical compositions
|
|
WO2012078902A2
(en)
|
2010-12-08 |
2012-06-14 |
Proteostasis Therapeutics, Inc. |
Proteostasis regulators
|
|
WO2012078909A1
(en)
|
2010-12-08 |
2012-06-14 |
Proteostasis Therapeutics, Inc. |
Thiazolpyrimidine proteostasis regulators
|
|
WO2012154880A1
(en)
|
2011-05-09 |
2012-11-15 |
Proteostasis Therapeutics, Inc. |
Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
|
|
HUE044867T2
(hu)
*
|
2011-05-12 |
2019-11-28 |
Proteostasis Therapeutics Inc |
Proteosztázis szabályzók
|
|
EP2806875B1
(en)
|
2012-01-25 |
2017-07-19 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating compounds
|
|
AU2013202373B2
(en)
|
2012-01-25 |
2016-04-14 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|
|
US9849135B2
(en)
*
|
2013-01-25 |
2017-12-26 |
President And Fellows Of Harvard College |
USP14 inhibitors for treating or preventing viral infections
|
|
WO2014210159A1
(en)
|
2013-06-26 |
2014-12-31 |
Proteostasis Therapeutics, Inc. |
Methods of modulating cftr activity
|
|
WO2015073528A1
(en)
|
2013-11-12 |
2015-05-21 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|
|
CA2942386A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
WO2015138934A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
CA2952862A1
(en)
|
2014-06-19 |
2015-12-23 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
|
CN104478780B
(zh)
*
|
2014-11-17 |
2017-04-19 |
华东师范大学 |
酰基吡咯类小分子有机化合物及其衍生物、用途及其制备方法
|
|
WO2016105468A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
CA2971850A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
US10738011B2
(en)
|
2014-12-23 |
2020-08-11 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
MA42488A
(fr)
|
2015-07-24 |
2018-05-30 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
WO2017040606A1
(en)
|
2015-08-31 |
2017-03-09 |
Proteostasis Therapeutics, Inc. |
Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders
|
|
CA3000483C
(en)
|
2015-10-06 |
2024-02-13 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for modulating cftr
|
|
MA44126A
(fr)
|
2015-12-22 |
2018-10-31 |
Proteostasis Therapeutics Inc |
Méthodes de traitement de maladies et troubles pulmonaires
|
|
BR112018070747B1
(pt)
|
2016-04-07 |
2024-01-09 |
Proteostasis Therapeutics, Inc |
Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
|
|
CA3023512A1
(en)
|
2016-05-09 |
2017-11-16 |
Proteostasis Therapeutics, Inc. |
Methods of identifying cftr modulators
|
|
MA45397A
(fr)
|
2016-06-21 |
2019-04-24 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
WO2018081381A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc |
Pyridazine derivatives, compositions and methods for modulating cftr
|
|
WO2018081378A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for modulating cftr
|
|
CA3041675A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc. |
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
|
|
MA49061A
(fr)
|
2017-04-28 |
2021-04-21 |
Proteostasis Therapeutics Inc |
Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
|
|
AU2018346602B2
(en)
|
2017-10-06 |
2024-10-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods for increasing CFTR activity
|
|
WO2020006269A1
(en)
*
|
2018-06-27 |
2020-01-02 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|